Applied BioCode (6598.TW) Stock Price
Applied BioCode Price
Revenue has compounded at 27.1% per year over the past 12 years to 475.20 M TWD. Applied BioCode's net margin stands at -42.3%, up from -51.6% several years earlier. The stock trades about 45% above its 52-week low.
Applied BioCode stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Applied BioCode over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Applied BioCode stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Applied BioCode's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Applied BioCode Price |
|---|---|
| 8/31/2026 | 28.55 TWD |
| 8/28/2026 | 29.00 TWD |
| 8/27/2026 | 29.00 TWD |
| 8/26/2026 | 27.85 TWD |
| 8/25/2026 | 27.70 TWD |
| 8/24/2026 | 27.85 TWD |
| 8/21/2026 | 28.55 TWD |
| 8/20/2026 | 27.95 TWD |
| 8/19/2026 | 27.60 TWD |
| 8/18/2026 | 27.75 TWD |
| 8/17/2026 | 28.50 TWD |
| 8/14/2026 | 27.80 TWD |
| 8/13/2026 | 27.75 TWD |
| 8/12/2026 | 27.80 TWD |
| 8/11/2026 | 27.65 TWD |
| 8/10/2026 | 28.80 TWD |
| 8/7/2026 | 28.80 TWD |
| 8/6/2026 | 30.15 TWD |
| 8/5/2026 | 31.10 TWD |
| 8/4/2026 | 31.50 TWD |
| 8/3/2026 | 31.00 TWD |
| 7/31/2026 | 30.20 TWD |
| 7/30/2026 | 28.75 TWD |
| 7/29/2026 | 29.85 TWD |
| 7/28/2026 | 29.10 TWD |
| 7/27/2026 | 30.00 TWD |
| 7/24/2026 | 27.70 TWD |
| 7/23/2026 | 28.80 TWD |
| 7/22/2026 | 27.85 TWD |
| 7/21/2026 | 26.65 TWD |
Applied BioCode Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Applied BioCode Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM TWD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM TWD |
| EBITM TWD |
| EBIT MARGIN% |
| NET INCOMEM TWD |
| NET INCOME GROWTH% |
| SHARESM |
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26.00 | 15.00 | 23.00 | 11.00 | 26.00 | 37.00 | 104.00 | 299.00 | 319.00 | 390.00 | 395.00 | 343.00 | 475.00 | – |
| – | -42.31 | 53.33 | -52.17 | 136.36 | 42.31 | 181.08 | 187.50 | 6.69 | 22.26 | 1.28 | -13.16 | 38.48 | – |
| 7.69 | 13.33 | 26.09 | 36.36 | 30.77 | 43.24 | 50.00 | 64.55 | 59.25 | 60.00 | 67.85 | 59.18 | 54.74 | – |
| 2.00 | 2.00 | 6.00 | 4.00 | 8.00 | 16.00 | 52.00 | 193.00 | 189.00 | 234.00 | 268.00 | 203.00 | 260.00 | 260.00 |
| -83.00 | -162.00 | -221.00 | -194.00 | -263.00 | -267.00 | -273.00 | -99.00 | -162.00 | -181.00 | -186.00 | -277.00 | -223.00 | – |
| -319.23 | -1,080.00 | -960.87 | -1,763.64 | -1,011.54 | -721.62 | -262.50 | -33.11 | -50.78 | -46.41 | -47.09 | -80.76 | -46.95 | – |
| -208.00 | -71.00 | -21.00 | -135.00 | -263.00 | -268.00 | -280.00 | -103.00 | -165.00 | -184.00 | -164.00 | -260.00 | -201.00 | – |
| – | -65.87 | -70.42 | 542.86 | 94.81 | 1.90 | 4.48 | -63.21 | 60.19 | 11.52 | -10.87 | 58.54 | -22.69 | – |
| 102.65 | 102.65 | 102.65 | 40.05 | 46.66 | 59.42 | 71.16 | 81.59 | 81.73 | 81.69 | 81.77 | 102.79 | 102.65 | 102.65 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Applied BioCode generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Applied BioCode retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Applied BioCode's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Applied BioCode has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Applied BioCode's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Applied BioCode stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Applied BioCode Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Applied BioCode business model & stock analysis
Applied BioCode SWOT Analysis
Strengths
Applied BioCode Corp has a strong and experienced team of scientists and researchers, enabling them to develop innovative products and solutions for the healthcare industry. The company has a diverse product portfolio, offering a range of diagnostic tests and systems to cater to various medical needs. Their advanced technology and automated systems provide accurate and efficient results, enhancing patient care.
Weaknesses
One of the weaknesses of Applied BioCode Corp is its relatively limited market presence compared to some competitors. They may face challenges in establishing themselves as a recognized brand in the highly competitive healthcare industry. Additionally, the company's dependency on third-party suppliers for certain components or materials may pose a risk to their supply chain management.
Opportunities
Applied BioCode Corp has opportunities to expand its market reach by targeting emerging markets and exploring collaborations with strategic partners worldwide. With the growing demand for personalized medicine and precision diagnostics, the company can further capitalize on its technology and expertise. They can also leverage advancements in digital health and data analytics to enhance their product offerings and improve patient outcomes.
Threats
The healthcare industry is subject to rigorous regulations and standards, which can pose challenges for companies like Applied BioCode Corp. Compliance with these regulations and obtaining necessary approvals for their products can be time-consuming and costly. Additionally, the company faces competition from established players in the diagnostic industry, who may have greater resources and market presence.
Applied BioCode Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Applied BioCode historical P/E ratio, EBIT multiple, and P/S ratio
Applied BioCode annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Applied BioCode shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Applied BioCode shareholder structure
| % | Name |
|---|---|
9.73018% | |
9.16736% | |
3.94085% | |
3.06682% | |
3.01164% | |
2.48303% |
Applied BioCode Beneficial Ownership Filings (SEC 13D/G)
Applied BioCode Executives and Management Board
14 members · 0 % women
Management
Mr. Zohn-Zen Ho
Founder, Chief Technology Officer, General Manager, Director · since 2008
Mr. Liang-Kai Huang
Chief Financial Officer, Corporate Governance Officer
Mr. Michael Aye
Vice President-Molecular Products
Mr. Donald Wong
Vice President-Productions
Mr. Youning Chen
Deputy General Manager-Taiwan Sub-Subsidiary
Gerald Kowalski
Deputy General Manager-Operation
Board of Directors
Mr. Jia-Long Lee
Chairman of the Board · since 2016
Mr. Benjamin Jen
Director
Lizzie Lee
Director
Mr. Wen-Jing Tsai
Independent Director
James Tsu
Independent Director
Jim Wu
Independent Director
Frequently asked questions about Applied BioCode
The business model of Applied BioCode Corp is centered around providing innovative molecular diagnostics solutions. They specialize in the development, manufacture, and commercialization of barcode technology-based multiplex testing systems for diagnostics laboratories. With their proprietary BioCode-1000 system, they offer a cost-effective and scalable solution for high-throughput testing of various diseases such as cancer, infectious diseases, and genetic disorders. Applied BioCode Corp aims to improve patient outcomes by delivering accurate and timely diagnostic results to healthcare professionals. Their advanced technology, coupled with a commitment to continuous innovation, positions them as a leading player in the field of molecular diagnostics.
Applied BioCode Corp is primarily active in the biotechnology industry.
The main competitors of Applied BioCode Corp in the market include companies such as Illumina, Thermo Fisher Scientific, Abbott Laboratories, Bio-Rad Laboratories, and QIAGEN.
Applied BioCode Corp is a leading biotechnology company specializing in developing and commercializing molecular diagnostic systems. Founded in [insert year], Applied BioCode Corp has a rich history in the field of biotech and has consistently delivered innovative solutions for healthcare professionals. The company is dedicated to improving patient care by revolutionizing diagnostic testing through its proprietary barcoded magnetic bead technology. With a team of highly skilled scientists and engineers, Applied BioCode Corp has gained recognition for its advanced diagnostic platforms that offer high throughput, multiplex capability, and cost-effectiveness. The company continues to expand its product portfolio and collaborate with industry partners to address the evolving needs of the healthcare industry.
Applied BioCode Corp has achieved several significant milestones in its journey. The company has made strides in the development and commercialization of its proprietary Barcoded Magnetic Bead (BMB) technology. This innovative technology offers multiplex testing capabilities, enabling simultaneous analysis of multiple targets, including genes, proteins, and pathogens. Applied BioCode Corp has successfully launched its FDA-cleared BioCode MDx 3000 system, which allows complex diagnostic testing with high precision and speed. Additionally, the company has secured strategic partnerships and collaborations with major healthcare institutions, facilitating the adoption of its BMB technology. Through these achievements, Applied BioCode Corp has established itself as a leader in the field of molecular diagnostics.
Applied BioCode Corp is primarily present in the United States, particularly in the state of California.
Applied BioCode Corp is a prominent biotechnology company that values innovation, integrity, and excellence. With a strong corporate philosophy, Applied BioCode Corp focuses on developing cutting-edge technologies and solutions to revolutionize diagnostics and improve patient care. By merging the fields of molecular diagnostics and multiplex biomarker detection, the company aims to address unmet clinical needs. Applied BioCode Corp is committed to providing accurate and efficient diagnostic products that empower healthcare professionals and ultimately enhance patient outcomes. With its forward-thinking approach and commitment to quality, Applied BioCode Corp strives to contribute to the advancement of healthcare and improve global health outcomes.
9 analysts currently rate the Applied BioCode stock: 0 recommend buying, 3 holding and 6 selling.
Converted at the current exchange rate, the Applied BioCode share trades at 0.78 EUR (28.55 TWD).
Applied BioCode Corp is a leading company in the field of molecular diagnostics and the development of digitally encoded barcode assays using multiple microbeads. The company utilizes its proprietary barcodes to enable complex biochemical analysis with high accuracy, reliability, and throughput capacity. The business model of Applied BioCode Corp is based on the development and commercialization of diagnostic systems and products for food and water analysis, clinical diagnostics, and research. The company offers innovative solutions to meet the needs of customers in various industries. Applied BioCode Corp's main division is the BioCode Gastrointestinal Pathogen Panel (GPP) diagnostic system, which allows for rapid and accurate diagnosis of gastrointestinal tract infections by simultaneously analyzing multiple samples for different bacteria, viruses, and parasites. Another product of the company is the BioCode Respiratory Pathogen Panel (RPP) system, which enables rapid and accurate diagnosis of respiratory infections by simultaneously analyzing multiple samples for different viruses and bacteria. The RPP provides an effective method for prevention, containment, and control of infectious diseases. Applied BioCode Corp also produces labeling products such as BioCode screening platforms to enable customers to accurately and timely identify pathogens. The company also offers a wide range of sampling methods and accessories to meet the requirements of diverse customers and applications. Applied BioCode Corp's products are distributed worldwide and are used in various industries, such as food and water analysis, clinical diagnostics, and research. The company focuses on offering innovative solutions to its customers to help meet their needs in terms of analysis, diagnosis, and results. Applied BioCode Corp also operates partnerships and collaborations with other companies to introduce and further develop its systems and products in new areas. The company is constantly striving to improve the quality and accuracy of its products while reducing costs to ensure high customer satisfaction. In conclusion, Applied BioCode Corp is a company that specializes in the development and commercialization of innovative diagnostic systems and products for food and water analysis, clinical diagnostics, and research. It offers its customers accurate and reliable solutions to meet their requirements and enhance their efficiency. With an advanced product portfolio, global trade partners, and a dedicated team of professionals, Applied BioCode Corp is undoubtedly one of the leading companies in the field of molecular diagnostics. Applied BioCode Corp is a leading company specializing in molecular diagnostics and the development of digitally encoded barcode assays using multiple microbeads. The company utilizes its proprietary barcodes to enable highly accurate, reliable, and high-throughput complex biochemical analyses. Their business model focuses on developing and marketing diagnostic systems and products for food and water analysis, clinical diagnostics, and research. They offer innovative solutions to meet the needs of customers in various industries. One of their main divisions is the BioCode Gastrointestinal Pathogen Panel (GPP) diagnostic system, which allows for rapid and accurate diagnosis of gastrointestinal infections by simultaneously analyzing multiple samples for various bacteria, viruses, and parasites. Another product is the BioCode Respiratory Pathogen Panel (RPP) system, providing fast and accurate diagnosis of respiratory infections by simultaneously analyzing multiple samples for different viruses and bacteria. The RPP offers an effective method for prevention, containment, and control of infectious diseases. Applied BioCode Corp also manufactures labeling products such as BioCode screening platforms, allowing for precise and timely identification of pathogens. They also offer a wide range of sampling methods and accessories to fulfill the requirements of different customers and applications. Their products are distributed worldwide and utilized in various industries including food and water analysis, clinical diagnostics, and research. The company focuses on providing customers with innovative solutions to fulfill their analytical, diagnostic, and result-related needs. They also engage in partnerships and collaborations with other companies to introduce and advance their systems and products in new areas. Applied BioCode Corp is committed to continuously improving the quality and accuracy of their products while reducing costs to ensure high customer satisfaction. In conclusion, Applied BioCode Corp is a specialized company that develops and markets innovative diagnostic systems and products for food and water analysis, clinical diagnostics, and research. Their accurate and reliable solutions help customers meet their requirements and increase efficiency. With their advanced product portfolio, global trade partnerships, and dedicated professional team, Applied BioCode Corp is a leading company in the field of molecular diagnostics.
The revenue cannot currently be calculated for Applied BioCode.
The profit cannot currently be calculated for Applied BioCode.
The P/E ratio cannot be calculated for Applied BioCode at the moment.
The P/S cannot be calculated for Applied BioCode currently.
The Eulerpool Quality Score for Applied BioCode is 4/10.
The ISIN of Applied BioCode is KYG0488D1051. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Applied BioCode is 6598.TW. The ticker symbol is used to trade Applied BioCode shares on the stock exchange.
Applied BioCode paid dividends every year for the past 0 years.
Applied BioCode is assigned to the 'Health' sector.
The dividends of Applied BioCode are distributed in TWD.
Applied BioCode stock
Applied BioCode Peer Group
Applied BioCode Ticker
Applied BioCode FIGI
All fundamentals and in-depth analysis of Applied BioCode
Our stock analysis for Applied BioCode stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Applied BioCode. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.